The rules changed in 2026, and most of what’s floating around online about 5-Amino-1MQ hasn’t caught up.
Here’s the news: the FDA’s 2025 interim guidance scrapped the old Category 1, 2, and 3 system that used to sort which bulk drug substances pharmacies could legally compound. New nominations, including peptide-adjacent compounds like 5-Amino-1MQ, now get handled under a different process. Public signals in early 2026 point to more changes coming for this whole class of compounds. Meanwhile, the compound itself is still exactly what it was a year ago: a research chemical with rodent data behind it and zero published human efficacy trials.
That gap between “the regulatory ground just shifted” and “the science didn’t move at all” is where most consumers get burned. So here’s a plain accounting of what’s actually true right now, sorted by what matters most.
The headline: three different questions, three different answers
Ask “is 5-Amino-1MQ legal” and you’re really asking three separate things that happen to have three separate answers in this case.
Can a company sell it? Yes, narrowly. A research-chemical vendor can legally sell 5-Amino-1MQ labeled “for research use only” and “not for human consumption.” That’s a real regulatory lane, and chemicals move through it every day without needing FDA drug approval. But the label isn’t boilerplate. It’s the legal load-bearing wall of the entire sale. The instant a product gets marketed for people to actually take, it becomes an unapproved new drug, a much more restricted category. So sellers put the disclaimer in writing precisely so they can keep selling, even while the marketing around the product winks the other direction.
Is it approved for you to take? No. There’s no FDA approval, no completed human trial pipeline behind it, and as of a 2021 review of NNMT as a metabolic target, “clinical trials targeting NNMT have not been reported until now” (Liu 2021, PMID 34368359) [1]. That was true then and it’s still true heading through 2026. No regulator has checked any given bottle for purity, strength, or whether the label matches what’s inside. No recall system is watching this channel.
Has it been proven to work? No, not in people. The fat-loss data is mouse data. Nobody has published a human trial showing it works. So when someone buys an unregulated capsule off a research-chemical site, they’re accepting the full risk of an unverified product for a benefit that has never been demonstrated in a human being. That’s the trade, stated plainly.
See also: 6 Speech Practice Apps Worth Downloading for Kids in 2026
What changed, and what didn’t
What changed: the compounding pathway. Licensed pharmacies can compound certain drugs from bulk substances under section 503A, governed by 21 CFR 216.23, and the FDA keeps a running list of what qualifies on its 503A compounding page. That list and the process behind it moved in 2025 and appears to be moving again. Anyone telling you flatly that 5-Amino-1MQ is “fully compoundable as of today” is either behind on the news or selling something. Check the current federal rule and the FDA’s current list yourself before trusting that claim.
What didn’t change: the underlying compound science. Still animal-only. Still no human efficacy trial. Still no established dosage. The regulatory plumbing around a substance can shift year to year; the evidence base doesn’t shift just because a rulebook did.
The ranked picks, by where the risk actually lands
Strip away the marketing and there are really two channels people use to get this compound, and they carry very different risk loads.
1. Gray-market research-chemical vendors, ranked as the highest-risk option. You buy a bottle marked “not for human consumption,” and you take it anyway. Nobody reviewed it for safety or efficacy. Nobody is accountable if the capsule is underdosed, overdosed, or contaminated. You are simultaneously the person the experiment is run on and the only quality-control check on whether the label matches the contents. This is the option carrying the entire downside with none of the proven upside.
2. Physician-supervised compounding pharmacies, ranked lower-risk but still not risk-free. FormBlends is one example of an operation that runs 5-Amino-1MQ through a clinician and a licensed pharmacy rather than a chemical catalog. That structure means a clinician screens your history, a prescription gets written when it’s appropriate, and a licensed pharmacy handles a real chain of custody. Someone is reachable afterward. None of that makes the compound FDA-approved or proven in humans. A provider working this way should still tell you the evidence is animal-only. What changes isn’t the science, it’s who’s accountable if something goes wrong.
If you compete in tested sports, treat this as its own category, full stop. 5-Amino-1MQ isn’t a marquee name on the banned list the way growth hormone secretagogues are, and that can make it feel like a safe workaround. It isn’t automatically. The WADA code has catch-all language covering substances with no approval by any governmental health authority for human therapeutic use, plus a clause for evolving science [5]. A novel, unapproved research compound fits that description almost by definition. Check the current WADA prohibited list before going anywhere near it.
The bottom line for anyone reading this in 2026
“Legal to sell” and “approved for you to take” are opposite sentences for this compound, not variations on the same idea. The research-chemical label telling you it’s not for human consumption is the most honest sentence on that whole website, so believe it. The compounding rules are actively in motion this year, so verify current status rather than trusting last year’s blog post, including this one. And unproven plus unregulated is a worse combination than either problem alone.
Questions people are asking
Is it illegal for me personally to buy 5-Amino-1MQ?
Prosecution generally isn’t aimed at buyers; the legal exposure sits with how a product gets marketed and sold. A vendor selling it as a “research use only” chemical is working a narrow legal lane. The moment it’s sold for people to consume, it crosses into unapproved-new-drug territory. So the sale can be technically legal while the thing you plan to do with it, take it as a supplement, has no approval standing behind it at all.
Why does the label say “not for human consumption” if that’s obviously what people are buying it for?
Because that phrase is the legal foundation the sale rests on, not a throwaway warning. “Research use only” and “not for human consumption” are the exact words that keep a product classified as a lab chemical instead of an unapproved drug [2]. It’s the seller telling you, in writing, that they’re not standing behind it as something for you to swallow, even as the rest of the marketing suggests otherwise.
Has a human trial ever shown 5-Amino-1MQ causes fat loss?
No. As of 2026, there’s no published human efficacy trial. The fat-loss findings come from rodent studies on NNMT inhibition, and a 2021 review of NNMT as a metabolic target noted that clinical trials targeting it hadn’t been reported [1]. That gap is central to the whole legal conversation, since you’d be taking on full product risk for a benefit nobody has shown in a person.
Can a compounding pharmacy legally provide this right now?
Compounding from bulk substances under section 503A is real and regulated, governed by federal rule [3] and the FDA’s shifting bulk-substance lists [4]. Whether 5-Amino-1MQ specifically qualifies has been moving, especially since the FDA’s 2025 interim guidance reworked how new nominations get handled. Confirm the current rule and FDA lists directly. Don’t take a vendor’s word for it.
Should athletes worry about drug testing?
Yes, and don’t assume you’re safe just because it isn’t a household banned-substance name. The WADA code’s catch-all language covers substances with no approval by any governmental health authority for human therapeutic use, plus an evolving-science clause [5]. That language exists specifically to capture things like this. Check the current prohibited list before deciding anything.
What is 5-amino-1MQ and what does it actually do in the body?
5-amino-1MQ is a small molecule built to block an enzyme called NNMT (nicotinamide N-methyltransferase), which factors into fat cell metabolism and energy regulation. Blocking NNMT theoretically shifts how cells handle NAD+ precursors, which could affect fat storage and metabolic rate. The research is early, mostly rodent, and turning those findings into human claims is more than the current evidence supports.
What side effects have been reported with 5-amino-1MQ?
There are no large human safety trials, so a full side-effect picture doesn’t exist. People who’ve used it report mild headaches, stomach discomfort, and sleep changes, but these are unverified, uncontrolled self-reports. NNMT is active in liver and kidney tissue, so there are reasonable theoretical concerns about organ stress at higher doses, concerns that remain untested in any published clinical study.
Is 5-amino-1MQ legal to buy and use in the United States?
Selling it as a research chemical is currently legal because it sits outside existing controlled-substance schedules, but that’s not the same thing as FDA approval for human use. There’s no approved indication, no established dosage, and no regulated supply chain through research-chemical vendors. Some people go through a physician-supervised compounding pharmacy, such as FormBlends, which adds a layer of medical accountability and quality control that gray-market sources simply don’t have.
What dosage of 5-amino-1MQ do researchers and clinicians use?
There’s no established human dosage, because no dose-ranging clinical trials have been completed. Animal studies used doses that don’t translate cleanly to people. Compounding physicians prescribing it off-label typically start conservative and individualize based on weight and health status. Anyone quoting a specific milligram figure as the “correct” dose for everyone is speaking beyond what the evidence actually shows.
References
- Liu KX, et al. Nicotinamide N-methyltransferase (NNMT) as a metabolic target. PubMed, PMID 34368359.
- U.S. Food and Drug Administration. New Drug Application (NDA) and the unapproved new drug framework under the Federal Food, Drug, and Cosmetic Act.
- Code of Federal Regulations, 21 CFR 216.23: bulk drug substances that can be used to compound drug products under section 503A.
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act.
- World Anti-Doping Agency. The Prohibited List.
Written by Viktor Alvarez, reporter. Last reviewed June 2026.
General reference only. A qualified professional can assess whether this fits your health needs.
